Direct reprogramming, inducing the conversion of one type of somatic cell into another by the forced expression of defined transcription factors, is a technology with anticipated medical applications.

During the reprogramming of somatic cells back into stem cells, gene regulation is controlled by pioneer transcription factors. These bind to the tightly packaged DNA in order to make it accessible.

Pluristyx, a leading provider of advanced induced pluripotent stem cell (iPSC) technologies and proprietary, genetically engineered solutions, today announced the Japanese Patent Office (JPO) issued a ...

A new study developed a mineralized DNA hydrogel that combines immune regulation with sustained bone regeneration. Using ...

Mesenchymal stromal cells (MSCs), also termed mesenchymal stem cells in the literature, have long been proposed for use in regenerative medicine and cell therapy. Currently, their therapeutic effects ...

Promising mouse studies and billions of dollars in funding are stoking excitement. But we’ve been here before.

Cellular reprogramming is the hottest topic in longevity science, with tech titans like Sam Altman investing in it. It's now ...

NewLimit Series C raises $435M led by Founders Fund as Armstrong-backed startup moves epigenetic therapies toward human trials.

For those hoping to cure death, and they are legion, a 2016 experiment at the Salk Institute for Biological Studies in San Diego has become liminal — the moment that changed everything. The experiment ...

Researchers have attained the holy grail of cellular reprogramming: inducing pluripotency without using any DNA-based materials. Using only a cocktail of purified proteins and a chemical additive, ...